Steven D. Rubin's most recent trade in Niagen Bioscience Inc. was a trade of 31,746 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Niagen Bioscience Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2026 | 31,746 | 31,746 | - | - | Stock Option (right to buy) | |
| Eloxx Pharma | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2026 | 4,018 | 4,018 | - | - | Stock Option (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2026 | 2,179 | 147,767 (1%) | 0% | - | Common Stock | |
| Entera Bio Ltd | Steven D. Rubin | Director | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 09 Feb 2026 | 10,000 | 10,000 (0%) | 0% | 1.2 | 12,000 | Ordinary Shares, par value NIS 0.0000769 per share |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 16,410 | 16,410 | - | - | Stock Options (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2025 | 4,450 | 145,588 (1%) | 0% | - | Common Stock | |
| Eloxx Pharma | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2025 | 179,854 | 179,854 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2025 | 1,875 | 1,875 | - | - | Restricted Stock Units | |
| Eloxx Pharma | Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2025 | 1,875 | 14,625 (0%) | 0% | - | Common Stock | |
| Niagen Bioscience Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 437,500 | 437,500 | - | - | Stock Option (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 19 Mar 2025 | 10,000 | 141,138 (1%) | 0% | 38.9 | 389,300 | Common Stock |
| Eloxx Pharma | Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 15,750 (0%) | 0% | 0 | Common Stock | |
| Eloxx Pharma | Steven D. Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2025 | 3,750 | 3,750 | - | - | Restricted Stock Units | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 8,000 | 151,138 (1%) | 0% | - | Common Stock | |
| Eloxx Pharma | D. Steven Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 12,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2024 | 18,957 | 2,660,242 (5%) | 0% | - | Common Stock | |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2024 | 437,500 | 6,625,232 (0%) | 0% | 0 | Common Stock | |
| Niagen Bioscience Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Eloxx Pharma | D. Rubin Steven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Opko Health Inc | D. Steven Rubin | Director, Executive VP-Administration | Purchase of securities on an exchange or from another person at price $ 0.87 per share. | 05 Jan 2024 | 10,000 | 6,187,732 (0%) | 0% | 0.9 | 8,669 | Common Stock |
| Red Violet Inc | Rubin Steven D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2023 | 10,800 | 143,138 (1%) | 0% | - | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 17,233 | 17,233 | - | - | Stock Options (Right to Buy) | |
| Niagen Bioscience Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Niagen Bioscience Inc | Steven D. Rubin | Director | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 25 May 2023 | 7,000 | 7,000 (0%) | 0% | 1.5 | 10,220 | Common Stock |
| Opko Health Inc | Steven D. Rubin | Director, Executive VP-Administration | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 700,000 | 700,000 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharma | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 2,859 | 2,859 | - | - | Stock Options (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2022 | 10,800 | 132,338 (1%) | 0% | - | Common Stock | |
| Cocrystal Pharma Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 188,000 | 188,000 | - | - | Stock Options (Right to Buy) | |
| Niagen Bioscience Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Eloxx Pharma | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Options (Right to Buy) | |
| Red Violet Inc | Steven D. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2021 | 8,900 | 121,538 (1%) | 0% | - | Common Stock |